A SPECIFIC TRIFLUOROETHYL QUINOLINE ANALOGUE FOR USE IN THE TREATMENT OF APDS

N-{(R)-1-[8-Chloro-2-(1-oxypyridin-3-yl)-quinolin-3-yl]-2,2,2-trifluoroethyl}-pyrido[3,2-d]pyrimidin-4-ylamine is effective in the treatment and/or prevention of activated phosphoinositide 3-kinase delta syndrome (APDS). La N-{(R)-1-[8-Chloro-2-(1-oxypyridin-3-yl)-quinolin-3-yl]-2,2,2-trifluoroéthyl...

Full description

Saved in:
Bibliographic Details
Main Authors MCHALE, Duncan Philip, KRACKER, Sven, CAVAZZANA, Marina, ALLEN, Rodger Anthony, ARMSTRONG, Martin John, PAYNE, Andrew Charles
Format Patent
LanguageEnglish
French
Published 23.11.2017
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:N-{(R)-1-[8-Chloro-2-(1-oxypyridin-3-yl)-quinolin-3-yl]-2,2,2-trifluoroethyl}-pyrido[3,2-d]pyrimidin-4-ylamine is effective in the treatment and/or prevention of activated phosphoinositide 3-kinase delta syndrome (APDS). La N-{(R)-1-[8-Chloro-2-(1-oxypyridin-3-yl)-quinolin-3-yl]-2,2,2-trifluoroéthyl}-pyrido[3,2-d]pyrimidin-4-ylamine est efficace dans le traitement et/ou la prévention du syndrome de PI3K-delta activée (APDS).
Bibliography:Application Number: WO2017EP61567